Deoxycytidine kinase Inhibitors
3 drugsAbout Deoxycytidine kinase
Deoxycytidine kinase (dCK) is an enzyme in the pyrimidine nucleoside salvage pathway, phosphorylating deoxycytidine for DNA incorporation. This phosphorylation is essential for DNA synthesis and cellular proliferation.
While there is no genetic evidence directly linking dCK to specific diseases, its role in DNA synthesis makes it a target in oncology. Inhibiting dCK disrupts DNA replication in cancer cells.
Three FDA-approved small molecule drugs target dCK: NELARABINE, ARRANON, and CLOFARABINE. These drugs are approved for oncology and other therapeutic areas, with Novartis, XGEN PHARMS, and PHARMOBEDIENT marketing them.
Top Deoxycytidine kinase Drugs
Three companies, PHARMOBEDIENT, XGEN PHARMS, and Novartis, have approved drugs targeting dCK.
The small number of players suggests relatively low competition, but also potentially high barriers to entry.
Deoxycytidine kinase Drug Modality Landscape
Modalities
Routes of Administration
Deoxycytidine kinase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation.
Deoxycytidine kinase Clinical Trials 114 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Deoxycytidine kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 44 | 27 | 13 | 4 | 68% |
| Phase 2 | 62 | 28 | 22 | 12 | 56% |
| Phase 3 | 8 | 5 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Deoxycytidine kinase Drug Approval Timeline (2005 - 2021)
The first drug targeting dCK was approved in 2005 (ARRANON), and the most recent in 2021 (NELARABINE).
The 17-year span suggests a sustained interest in dCK as a drug target, but also a potentially saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 54 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Deoxycytidine kinase. A trial counts if an approved drug acting on Deoxycytidine kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.